ESR1 and neoplasm: Consistently, our KEGG enrichment highlights estrogen signaling, endocrine resistance, and breast cancer pathways, supporting a model wherein these variants may blunt ERβ1’s tumor-suppressive signaling and bias cells toward ER-dependent growth and therapy resistance.